Adaptive Biotechnologies is trading at $24.00 (4.7% up) in pre-market, extending a strong multi-day uptrend that recently saw the stock surpass its previous 52-week high in the low-$22 range.
- The move appears to be a continuation of bullish sentiment following recent upside earnings surprises and growth driven by the company's Minimal Residual Disease (MRD) business.
- Positive analyst commentary reported over previous months continues to support the stock's trajectory despite a lack of fresh company-specific headlines since early July.
- Shares are currently testing new highs as technical momentum builds on the back of sustained buying pressure.